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COMMENTARY
Who should be prioritised for COVID-19 vaccination?
Fiona M Russell a,b and Brian Greenwoodc
aDepartment of Paediatrics, The University of Melbourne, Melbourne, Australia; bAsia-Pacific Health Research, Murdoch Children’s Research Institute, 
Melbourne, Australia; cDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, UK
ABSTRACT
The development of COVID-19 vaccines is occurring at a rapid pace, with the potential for a vaccine to be 
available within 6 months. So who should be prioritized for vaccination when in the first instance, there 
will be insufficient supply to meet demand? There is no doubt that health-care workers in all settings 
should be vaccinated first, but who comes next will be a complex decision based on local epidemiology, 
societal values, and the ability of the vaccines to prevent both severe disease and to reduce transmission 
thereby eliciting herd protection. The decision on who to vaccinate should be equitable, highly con-
textualized, and based on the property of each vaccine. In some settings, the elderly may be prioritized, in 
others, it may be the population most likely to get infected and responsible for community spread. To 
support decision-making on who to be prioritized for vaccination requires urgent additional research on 
the epidemiology of COVID-19; preexisting immunity and who is responsible for transmission in a variety 
of settings; the safety, immunogenicity, and efficacy of COVID-19 vaccines in children and pregnant 
women; and determining whether COVID-19 vaccines prevent asymptomatic infection and transmission.
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COVID-19 vaccines are being developed at a furious pace. 
There are already six vaccines in phase 3 clinical trials from 
Moderna/NIAID, University of Oxford/AstraZeneca, 
BioNTech/Fosun Pharma/Pfizer, and three from Chinese com-
panies, Sinovac, Wuhan Institute of Biological Products/ 
Sinopharm, and Beijing Institute of Biological Products/ 
Sinopharm.1 Hundreds of millions of doses of vaccine may be 
ready for roll-out by the end of 2020 or early 2021.
At least 14 high-income countries are prospectively buying 
vaccines before they have even been cleared for use.1 The US 
deals with Pfizer-BioNTech, AstraZeneca/Oxford, Sanofi- 
Glaxo, Moderna, Novovax, and Johnson & Johnson are using 
American buying power to avoid paying excessive prices. The 
UK has done deals with providers for more than 250 million 
doses of COVID-19 vaccines. Recently, Australia announced 
an agreement with AstraZeneca to buy 25 million doses pro-
vided the Oxford vaccine is safe and effective. The Coalition for 
Epidemic Preparedness Innovations (CEPI), which coordi-
nates the global COVID-19 vaccine development effort, 
together with the World Health Organization, and Gavi, The 
Vaccine Alliance, has developed the COVAX Facility to ensure 
equitable global access to COVID-19 vaccines once these are 
available.
Who should be prioritized once vaccines become available? 
In the first instance, not enough vaccines will be available for 
the entire global population of almost eight billion to be vacci-
nated, so difficult decisions will need to be made as to who gets 
vaccinated first, as prioritization is inevitable and some people 
will have to wait. There is general agreement that health-care 
workers in all settings, should be vaccinated first, not only for 
their own benefit, but also to ensure the effective running of the 
health system. In the UK and the USA, the risk of reporting 
a positive test for COVID-19 was 11-fold higher among front- 
line health-care workers compared to the general public.2
After health-care workers, who should be next? Herein lies 
profound societal and ethical dilemmas- should the elderly, 
who are most at risk of severe disease and death, be the target, 
or should the age groups that transmit the virus most fre-
quently and who are most engaged in the economic function-
ing of society be vaccinated next? There are already indications 
that the pandemic and mitigation measures are having broad 
indirect health effects. In the UK, there are delays in cancer 
screening, diagnosis, and subsequent treatment services due to 
changes in service delivery or fear of going out, which may 
result in thousands of excess deaths.3 Where SARS-CoV-2 
population-based testing rates are high, people aged 
20–49 years have consistently been shown to have high SARS- 
CoV-2 infection rates.4,5 Hence, strategically vaccinating those 
most likely to get infected and to transmit the infection could 
also protect most of the community through herd protection, 
allowing the workforce to function and preventing the indirect 
adverse societal and health effects of the epidemic. Herd pro-
tection has been demonstrated in varying degrees for a number 
of vaccines including the pneumococcal conjugate vaccine, 
with vaccination of young children (the age group most 
responsible for transmitting pneumococci) protecting the 
elderly from pneumococcal disease through indirect effects.6
Deciding how much priority to give to direct protection, i.e. 
preventing severe disease in high-risk groups, or to the indirect 
effects, i.e. preventing overall transmission in the community 
(and the high-risk groups), and allowing everyday activities to 
resume with consequent economic benefits to the whole com-
munity, will be a challenge for public health authorities. 
Workers in high-risk employment could be given priority. 
CONTACT Fiona M. Russell fmruss@unimelb.edu.au Department of Paediatrics, The University of Melbourne, Melbourne, Australia
HUMAN VACCINES & IMMUNOTHERAPEUTICS     
https://doi.org/10.1080/21645515.2020.1827882
© 2020 Crown Copyright. Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), 
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
The Swedish Public Health Authority compared SARS-CoV-2 
infection risk by profession in their country, and found that 
front-line workers such as taxi drivers, pizza chefs, and public 
transport drivers had more than a four-fold higher risk of 
infection than other workers. In contrast, Swedish teachers 
and childcare workers had no increased risk compared to 
other professions.7
Decisions on which vaccine to use will depend on the 
vaccine’s properties in terms of efficacy against severe disease 
and transmission, and whether the desired public health out-
come is to prevent severe disease and/or to prevent transmis-
sion. Ideally, a COVID-19 vaccine will do both. There are early 
indications that some vaccines are immunogenic in clinical 
trials,8–10 and prevent disease in non-human primate models. 
Yet some vaccines may be less effective in preventing transmis-
sion, as demonstrated by the lack of difference in nasal shed-
ding of the virus between vaccinated and unvaccinated 
groups.11 It is imperative that clinical trials include SARS- 
CoV-2 viral shedding outcomes, and that further progress is 
made on how to measure indirect protection and demonstrate 
the ability of a vaccine to prevent asymptomatic infection and 
transmission.
If prioritizing people to be vaccinated is decided according 
to risk, then age is a key factor as in many studies from high- 
income studies, the elderly had a much higher risk of death 
from COVID-19 than the young, with a dramatic and progres-
sive increase in risk in those over 65 years of age.12 In the case 
of some other vaccines, such as influenza, the elderly require 
more antigen to develop a protective immune response, and 
more antigen in each dose may result in more side effects.13 
Some COVID-19 vaccine developers are, therefore, looking at 
different dosage regimens for this age group and also at the use 
of powerful adjuvants. When the vaccine is in short supply, 
whether to include the very old as a priority group becomes an 
ethical issue, one that each country will need to consider based 
on what’s acceptable to their population. Traditionally, vac-
cines need to show disability adjusted life years saved 
(DALYs)- this is the sum of the years of potential life lost due 
to premature mortality and the years of productive life lost due 
to disability. For the very old, the number of DALYs saved by 
vaccination will be quite low, as one DALY represents the loss 
of the equivalent of 1 year of full health. As the average life 
expectancy at birth varies considerably across the world, the 
proportion of the population who will require vaccination if 
this focuses on the elderly will vary by country.14 In low- 
income countries, only a small proportion of the population 
would be considered elderly, so other factors will be important 
in terms of setting priorities on who to vaccinate.
Other key risk factors that predict the risk of death from 
COVID-19 include the presence of co-morbidities. A study 
from the UK found diabetes, severe asthma and various other 
medical conditions, including hypertension, to be risk factors 
for a COVID-19 related death.12 A modeling study estimated 
that 1.7 billion people, comprising 22% of the global popula-
tion, have at least one underlying condition that puts them at 
increased risk of severe COVID-19 infection (ranging from 
<5% of those younger than 20 years to >66% of those aged 
70 years or older).15 The proportion of the population at 
increased risk was highest in countries with older populations, 
African countries with a high HIV/AIDS prevalence, and small 
island nations (such as Pacific island and Caribbean countries) 
with a high prevalence of diabetes. Estimates of the number of 
individuals at increased risk were most sensitive to the preva-
lence of chronic kidney disease, diabetes, cardiovascular dis-
ease, and chronic respiratory disease.15 In South Africa, a study 
found that HIV doubled the mortality risk from COVID-19, 
and previous tuberculosis had a similar impact.16
Variations in the epidemiology of the infection in different 
geographical locations, which are still not fully understood, will 
make it necessary to weight the balance between different risk 
factors in each geographical region. There are very few data 
from low- and middle-income countries (LMIC) regarding 
who is most at risk of a severe COVID-19 outcome. The 
epidemiology of the infection may differ considerably in 
LMIC from that in high-income countries as the demography, 
household transmission dynamics, comorbidities by age group 
and access to life saving treatment, such as oxygen and inten-
sive care will be different. There is some suggestion that the 
mortality in Africa and India may be lower than in high- 
income countries and it is postulated that this could be due 
to differences in exposure to other infectious diseases which 
may alter trained immunity.17 Ethnicity may also be a key risk 
factor. In the UK, Black and South Asian people were at higher 
risk compared with people of White background, even after 
adjustment for other factors.12 A cross-sectional study from 
Brazil found that compared with White Brazilians, Pardo, and 
Black Brazilians with COVID-19 who were admitted to hospi-
tal had a significantly higher risk of mortality. Pardo ethnicity 
was the second most important risk factor (after age) for 
death.18 In some settings, indigenous populations are at high 
risk, and therefore have a case for priority.
Understanding risk factors for children and women is also 
critical because widespread poverty and malnutrition in LMICs 
may put these groups at enhanced risk. However, as yet, there 
are no studies to support this. There are very few studies of 
COVID-19 in pregnant women, especially from LMICs. The 
COVID-19 pandemic is likely to have substantial direct and 
indirect effects on perinatal outcomes in LMIC due to the 
direct effect of the virus and through disruption of routine 
essential maternity and newborn services.19 There are chal-
lenges to determining the true burden of COVID-19 in preg-
nancy as women are more likely to protect themselves from 
contracting COVID-19 by staying at home, for fear of infecting 
their unborn child, and are therefore not being tested and 
counted. Most of what is currently known of SARS-CoV-2 
during pregnancy is drawn from high-income countries. 
There is evidence of perinatal SARS-CoV-2 transmission but 
the clinical outcomes of the newborns have, so far, been 
favorable.20 Although data from the UK found that the risk 
of being infected with SARS-CoV-2 is no higher in pregnant 
women compared with non-pregnant women of child-bearing 
age,21 recent data from the US suggest the odds of requiring 
mechanical ventilation is 50–70% higher in pregnant women 
compared with non-pregnant women of child-bearing age.22 
A UK study found that obesity, diabetes, and being Black are all 
risk factors for hospital admission with SARS-CoV-2 during 
pregnancy.21 Deaths in non-pregnant people with type 1 and 
type 2 diabetes rose sharply during the initial COVID-19 
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pandemic in England. Increased COVID-19-related mortality 
was associated not only with cardiovascular and renal compli-
cations of diabetes but also, independently, with glycemic 
control and body mass index.23 In Brazil, most COVID-19- 
related deaths among pregnant women were reported between 
the age of 30–39 years, and diabetes, heart disease, obesity, 
hypertension, and asthma were linked to death.24 Small island 
countries in the Caribbean and the Pacific, with high rates of 
preexisting or gestational diabetes which is not well controlled, 
and limited access to oxygen and ICU support, may be a key 
target for vaccination.25 Yet it seems that very few COVID-19 
vaccine developers have pregnant women in their vaccine pipe-
line plan.26 Safety needs to be established first in otherwise 
healthy adults as enhanced disease is a potential risk of this 
vaccine.27 But what amount of safety data would be required to 
allow pregnant women to be included in clinical trials? 
Currently, there is only one vaccine developer including preg-
nant women in clinical trials.
In view of the data presented above, the priority groups 
for vaccination in high-income countries whose priority is 
to prevent deaths and severe disease are likely to be health- 
care workers, the elderly and those with a variety of co- 
morbidities, although both of the latter groups may need 
vaccines of enhanced potency. If transmission is to be 
stopped, targeting workers who are at high risk of infection 
and transmission and who cannot work from home and 
who are in contact with high-risk groups will be key. This 
would include workers in homes for the elderly, public 
transport workers, and those in the service industry- this 
will vary by setting. However, where do children, adoles-
cents, and young people feature in terms of prioritization 
for vaccination? Children have consistently been shown to 
have a lower burden of COVID-19 disease than adults and 
hence, at first, do not appear to be high on the priority list 
for vaccination. Young children are important drivers of 
other common respiratory viruses,28 but the role that they 
play in the transmission of SARS-CoV-2 virus in either 
high- or LMICs is still not fully determined. Studies have 
found that contact patterns vary by ethnicity and, as in the 
case of pneumococcal conjugate vaccines, the age group 
acting as an ongoing reservoir for infection shifts once 
a vaccine is introduced.29 School closures, which are so 
important during community transmission, mean that 
understanding transmission in this population is challen-
ging as studies are confounded by public health mitigation 
measures. Additionally, there are few studies that include 
serology and asymptomatic contacts which limits the 
understanding of true infection rates and transmission 
potential in this group. A comparison between Finland 
(which closed schools) versus Sweden (which did not, 
except for children >16 years who schooled remotely) reas-
suringly found that the rates of infection in day care centers 
and school children were no different between countries, 
and primary school closure and reopening in Finland did 
not have any significant impact on the weekly number of 
laboratory-confirmed cases in primary school-aged 
children.30
Nevertheless, outbreaks in schools and school camps have 
occurred so it is important to understand the conditions that 
enable this to happen. A study from Israel found that an 
extreme heatwave, necessitating the relaxation of mask wear-
ing and the need for air-conditioning, large numbers of 
children in a classrooms, and social contact through extra- 
curricular activities and travel by school bus, were all factors 
that contributed to a large outbreak in a secondary school.31 
In the US, an outbreak in attendees at a school summer camp 
found attack rates in children aged 6–10 years, 11–17 years, 
and 18–21 years to be extra-ordinarily high – 51%, 44%, and 
33%, respectively.32 These findings demonstrate that children 
are susceptible to SARS-CoV-2 infection and that they 
appear to efficiently spread SARS-CoV-2virus in some cir-
cumstances. In addition, a recent study found that children 
younger than 5 years old with mild to moderate COVID-19 
may have high amounts of SARS-CoV-2 viral RNA in their 
nasopharynx.33 Although this study did not detect infectious 
virus, other studies have found a correlation between high 
nucleic acid levels and the ability to culture infectious 
virus,34 suggesting that young children can potentially be 
important drivers of SARS-CoV-2 spread in the general 
population. In many countries, especially in LMIC, class-
room sizes are large, classrooms may be small in physical 
size, hand washing facilities are minimal or non-existent, and 
the heat may make the wearing of face masks unachievable, 
making public health control measures unrealistic.35 The 
school setting may be a very important reservoir and source 
for ongoing transmission and outbreaks. If this is the case, 
then vaccinating school-age children may be necessary to 
interrupt transmission. However, there are only three vac-
cine developers who are currently including children in 
clinical trials.
Ideally, the most effective way to return life to nor-
mal is a COVID-19 vaccine that prevents disease, pre-
vents asymptomatic infection, and stops transmission. 
However, when vaccine supply cannot meet demand, 
the decision on who to vaccinate needs to be an equi-
table one, highly contextualized, based on the properties 
of the vaccine and whether the reduction of severe 
disease, interruption of transmission or both are 
desired. Most importantly, governments need to make 
decisions based on their own local epidemiology, prio-
rities, and societal values. Therefore, there is an urgent 
need for further research on the epidemiology of 
COVID-19 and determining who is responsible for 
transmission in a variety of settings; the safety, immu-
nogenicity, and efficacy of COVID-19 vaccines in chil-
dren and pregnant women; and determining whether 
COVID-19 vaccines prevent asymptomatic infection 
and transmission.
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